Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIET: Pazopanib Tolerability with Food
NCT02138526Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2014
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pazopanib in renal cell carcinoma (RCC) and soft tissue sarcoma (STS) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Area under the plasma concentration versus time curve at 4 weeks. Started Jun 2014; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02138526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138526.